Status | Study |
Active, not recruiting |
Study Name: A Study of Single-dose MY008211A in Healthy Adults Condition: Paroxysmal Nocturnal Hemoglobinuria Date: 2022-11-30 Interventions: Interventional |
RECRUITING |
Study Name: Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan. Condition: Paroxysmal Nocturnal Hemoglobinuria Date: 2022-11-18 Interventions: Treatment with iptacopan at a dose of 200 mg b.i.d. will start on the first day (Day 1) and continue for 24 weeks. |
Active, not recruiting |
Study Name: To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104 Condition: Paroxysmal Nocturnal Hemoglobinuria Date: 2022-08-04 Interventions: Interventional |
Recruiting |
Study Name: Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) Date: 2017-03-08 Interventions: Drug: RA101495 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance d |
Not yet recruiting |
Study Name: ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) Date: 2017-02-14 Interventions: Biological: ALXN1210 |
Recruiting |
Study Name: A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) Date: 2017-02-01 Interventions: Drug: ACH-0144471 ACH-0144471 will be administered to all patients enrolled in the study. |
Recruiting |
Study Name: Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) Date: 2017-01-20 Interventions: Drug: RA101495 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance d |
Recruiting |
Study Name: Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria Condition: Paroxysmal Hemoglobinuria, Nocturnal Date: 2016-11-01 Interventions: Drug: RO7112689 RO7112689 will |
Recruiting |
Study Name: ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) Date: 2016-10-25 Interventions: Biological: ALXN1210 |
Active, not recruiting |
Study Name: A Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria Condition: Paroxysmal Nocturnal Hemoglobinuria PNH Date: 2015-11-11 Interventions: Biological: Study Drug- ALXN1210 |